Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Divided attention-enhancing effects of AF102B and THA in aging monkeys.

O'Neill J, Fitten LJ, Siembieda DW, Crawford KC, Halgren E, Fisher A, Refai D.

Psychopharmacology (Berl). 1999 Apr;143(2):123-30.

PMID:
10326774
2.

Reduction in distractibility with AF102B and THA in the macaque.

O'Neill J, Siembieda DW, Crawford KC, Halgren E, Fisher A, Fitten LJ.

Pharmacol Biochem Behav. 2003 Sep;76(2):301-6.

PMID:
14592682
3.

Effects of AF102B and tacrine on delayed match-to-sample in monkeys.

O'Neill J, Fitten LJ, Siembieda D, Halgren E, Kim E, Fisher A, Perryman K.

Prog Neuropsychopharmacol Biol Psychiatry. 1998 May;22(4):665-78.

PMID:
9682279
4.

Reduction of motoric agitation and restlessness by AF102B and tacrine in the macaque.

Fitten LJ, Ortiz F, Siembieda DW, O'Neill J, Halgren E, Fisher A.

J Neuropsychiatry Clin Neurosci. 1999 Winter;11(1):79-85.

PMID:
9990560
5.

Effects of a novel cholinergic M1 agonist, AF102B, on ambulation and water drinking behavior in rats.

Togashi H, Matsumoto M, Yoshioka M, Saito Y, Saito H.

Hokkaido Igaku Zasshi. 1991 Jan;66(1):59-66.

PMID:
2004736
6.

Effect of YM796, a novel muscarinic agonist, on the impairment of passive avoidance response in senescence-accelerated mice.

Suzuki M, Yamaguchi T, Ozawa Y, Iwai A, Yamamoto M.

Pharmacol Biochem Behav. 1995 Aug;51(4):623-6.

PMID:
7675834
7.

Effects of guanfacine on three forms of distraction in the aging macaque.

O'Neill J, Fitten LJ, Siembieda DW, Ortiz F, Halgren E.

Life Sci. 2000 Jul 14;67(8):877-85.

PMID:
10946847
8.

Memory-related task performance by aged rhesus monkeys administered the muscarinic M(1)-preferring agonist, talsaclidine.

Terry AV Jr, Buccafusco JJ, Borsini F, Leusch A.

Psychopharmacology (Berl). 2002 Jul;162(3):292-300. Epub 2002 May 29.

PMID:
12122487
9.

Sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze.

Hatcher JP, Loudon JM, Hagan JJ, Clark MS.

Psychopharmacology (Berl). 1998 Aug;138(3-4):275-82.

PMID:
9725749
10.

Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention.

Bushnell PJ, Oshiro WM, Padnos BK.

Psychopharmacology (Berl). 1997 Dec;134(3):230-41.

PMID:
9438673
11.
13.

Reversal of age-related cognitive impairments by an M1 cholinergic agonist, AF102B.

Brandeis R, Dachir S, Sapir M, Levy A, Fisher A.

Pharmacol Biochem Behav. 1990 May;36(1):89-95.

PMID:
2349275
14.

Effects of muscarinic and adrenergic agonism on auditory P300 in the macaque.

O'Neill J, Halgren E, Marinkovic K, Siembieda D, Refai D, Fitten LJ, Perryman K, Fisher A.

Physiol Behav. 2000 Jul 1-15;70(1-2):163-70.

PMID:
10978492
15.

Sympathoexcitatory action of a novel muscarinic receptor agonist, AF102B, and its blockade by pirenzepine.

Yoshioka M, Togashi H, Matsumoto M, Morii K, Saito H.

Pharmacol Toxicol. 1990 Jul;67(1):84-7.

PMID:
2395822
16.

Oral tacrine administration in middle-aged monkeys: effects on discrimination learning.

Fitten LJ, Perryman K, Tachiki K, Kling A.

Neurobiol Aging. 1988 Mar-Apr;9(2):221-4.

PMID:
3374739
17.

M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy.

Fisher A, Pittel Z, Haring R, Bar-Ner N, Kliger-Spatz M, Natan N, Egozi I, Sonego H, Marcovitch I, Brandeis R.

J Mol Neurosci. 2003;20(3):349-56. Review.

PMID:
14501019
18.

The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys.

Buccafusco JJ, Weiser T, Winter K, Klinder K, Terry AV.

Neuropharmacology. 2004 Jan;46(1):10-22.

PMID:
14654093
19.

(+-)-cis-2-methyl-spiro(1,3-oxathiolane-5,3') quinuclidine (AF102B): a new M1 agonist attenuates cognitive dysfunctions in AF64A-treated rats.

Fisher A, Brandeis R, Pittel Z, Karton I, Sapir M, Dachir S, Levy A, Heldman E.

Neurosci Lett. 1989 Jul 31;102(2-3):325-31.

PMID:
2812509
20.

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update.

Fisher A, Heldman E, Gurwitz D, Haring R, Karton Y, Meshulam H, Pittel Z, Marciano D, Brandeis R, Sadot E, Barg Y, Pinkas-Kramarski R, Vogel Z, Ginzburg I, Treves TA, Verchovsky R, Klimowsky S, Korczyn AD.

Ann N Y Acad Sci. 1996 Jan 17;777:189-96. Review.

PMID:
8624083

Supplemental Content

Support Center